Cortechs.ai | Predicting progression of MCI

Predicting progression of MCI

Predicting Progression of Mild Cognitive Impairment to Alzheimer’s Disease: Hippocampal Occupancy Score (HOC)

The NeuroQuant Dementia report includes a Hippocampal Occupancy (HOC) Score and volumes of the hippocampi, superior and inferior lateral ventricles, and the entorhinal cortex, which are important biomarkers used in predicting progression of Mild Cognitive Impairment (MCI) to Alzheimer’s disease (AD). As with all NeuroQuant reports, the brain structure volumes and the HOC are compared to healthy patients of the same age and sex, normalized for intracranial volume (ICV).

Current research has demonstrated the effectiveness of the HOC in assessing patient progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD). This proven biomarker is an invaluable factor in predicting the progression of neurodegenerative diseases as approximately 10 – 15% of all patients diagnosed with MCI will develop AD annually [1]. Hippocampal volume remains the best single predictor of conversion of MCI to AD at a 3-year follow-up [2].

The HOC measures the degree of hippocampal atrophy accounting for volume loss and compensatory inferior lateral ventricle (ILV) expansion. It is calculated as a ratio of hippocampal volume to the sum of the hippocampal and ILV volumes in each hemisphere separately, which are then averaged and normalized for age and sex. The equation is as follows:

Cortechs.ai | Predicting progression of MCI

 

The NeuroQuant Dementia report provides the HOC in the first row of the table below the segmented images. The HOC is then visualized on the graph below the table to the far left, where it is plotted against the age and sex normalized values. The normative range (5th – 95th percentile) is represented in the white area of the graph while the solid line represents the mean. 

Below are a few examples to better illustrate how the HOC is interpreted with the rest of the information provided on the NeuroQuant Dementia report.

Example Cases

Case 1: 

Cortechs.ai | Predicting progression of MCI

  • Two T1 MRI scans of a 67-year-old male patient.
  • HOC measures .69 cm3 which is within two standard deviations of the normative range for age and sex.
  • The hippocampi, lateral ventricles, and inferior lateral ventricles are all within two standard deviations of the normative range for age and sex.
  • Conclusion: Normal follow-up that does not support neurodegeneration or the progression from MCI to AD. 

Case 2:

Cortechs.ai | Predicting progression of MCI 

  • A single T1 MRI scan of a 36-year-old female.
  • HOC measures 0.66 cm3. The mesial temporal lobe is more than two standard deviations from the normative range for age and sex. 
  • The hippocampi demonstrate atrophy and are beyond two deviations below the normative range for age and sex.
  • The lateral ventricles and inferior lateral ventricles are enlarged beyond two standard deviations of the normative range for age and sex.

Conclusion: Low hippocampal volume and suggestive of local ex-vacuo dilatation. This supports mesial temporal lobe-focused neurodegenerative etiology. Suggestive of the progression from MCI to AD.

This measure not only aids in the differentiation of individuals with congenitally small hippocampi from those with small hippocampi due to a degenerative disorder but also effectively demonstrates the risk of conversion from MCI to AD. 

Citations:

[1] Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough

[2] Predictive Utility of Marketed Volumetric Software Tools in Subjects at Risk for Alzheimer Disease: Do Regions Outside the Hippo

More Resources

05/18/2025

Cortechs.ai and ALZ-NET Announce Strategic Collaboration to Improve Alzheimer’s Disease Care Through AI-Driven Imaging

This new strategic collaboration aims to enhance the quality of care for people living with Alzheimer’s disease.

05/16/2025

Case Study: NeuroQuant® for ARIA: Monitoring ARIA Progression in Early Alzheimer’s Disease

Dr. Suzie Bash highlights how advanced imaging with NeuroQuant for ARIA supported detection and monitoring of ARIA-E and ARIA-H in an 81-year-old patient.

05/13/2025

Dr. Ana M. Franceschi Joins Cortechs.ai Medical Advisory Board

Neuroimaging thought leader to enhance PET/MRI and dementia research impact through AI-powered tools

05/10/2025

All the Ways to Use the NeuroQuant Custom Report

With the ability to select structures from NeuroQuant’s 70+ structure parcellation atlas, the user has the power to truly personalize patient care!

05/04/2025

Introducing NeuroQuant MS Lesion Dynamics Computation: A Clearer Path to Understanding Disease Progression

Discover how the latest NeuroQuant MS update offers a clearer, more intuitive way to track lesion changes and understand disease progression over time.

05/02/2025

4 Reasons Why Over 1500 Medical Centers Worldwide Trust Cortechs.ai

Trusted by 1500+ medical centers, Cortechs.ai delivers AI-powered imaging tools that enhance diagnostic accuracy and streamline workflows.
Scroll to Top